After investing in a few biotech companies, one thing to avoid is a capital raise when cash reserves are running low. Such a situation often signals financial weakness which negatively impacts the stock price and leads to devastating dilution for the long term holders. You want to have plenty of cash on hand for any unexpected delays in this space and need to raise capital when you’re still in a position of strength. my 2c. DYOR
After investing in a few biotech companies, one thing to avoid...
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add EBR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.06 |
Change
-0.025(2.30%) |
Mkt cap ! $391.2M | |||
| Open | High | Low | Value | Volume |
| $1.09 | $1.09 | $1.04 | $226.0K | 211.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 250 | $1.04 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.06 | 2186 | 1 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| EBR (ASX) Chart |